Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Mark Roschewski, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Matthias Holdhoff, MD PhD, Lode J. Swinnen, MB ChB, Michael Glantz, MD PhD, Craig A. Portell, MD, Jakub Svoboda, MD, Rafic Farah, MD, Michail S. Lionakis, MD ScD, Louis Staudt, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2875.

https://doi.org/10.1182/blood-2019-123552

Published: 2019

Journal Articles

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

Sanjal Desai, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Mark A. Ahlman, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 4102.

https://doi.org/10.1182/blood-2019-127481

Published: 2019

Journal Articles

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

Ariela Noy, MD, Timothy S. Pardee, MD PhD, Liana Nikolaenko, MD, Raphael Eric Steiner, MD, Jeremy S. Abramson, MD MMSc, Kieron Dunleavy, MD, Sanjeev Luther, MBA

Blood (2019) 134 (Supplement_1): 4087.

https://doi.org/10.1182/blood-2019-131563

Published: 2019

Journal Articles

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Jaime P. Gastwirt, MD, Mark A. Ahlman, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Wyndham Wilson, MD, Mark Roschewski, MD

Blood (2019) 134 (Supplement_1): 4080.

https://doi.org/10.1182/blood-2019-122450

Published: 2019

Journal Articles

Short-Course Therapy in Newly Diagnosed Immunodeficiency-Associated Aggressive B-Cell Lymphoma

Rami Alsharif, MD, Samah Nassereddine, MD, Esma Akin, MD, Donald Karcher, MD, Mitchell Smith, MD PhD, Eduardo Sotomayor, MD, Kieron Dunleavy, MD

Blood (2019) 134 (Supplement_1): 5355.

https://doi.org/10.1182/blood-2019-124081

Published: 2019

Journal Articles

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

Fengdong Cheng, MD, Yuan Ren, PhD, Jie Chen, PhD, Zi Wang, B.S., Tao Li, MD, Kieron Dunleavy, MD, Jianqing Lin, MD, James Bradner, MD, Mitchell R. Smith, MDPhD, Bijal D. Shah, MD, Eduardo Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2018) 132 (Supplement 1): 777.

https://doi.org/10.1182/blood-2018-99-116865

Published: 2018

Journal Articles

Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma

Rahul Lakhotia, MD, Christopher Melani, MD, Stefania Pittaluga, MD PhD, Kieron Dunleavy, MD, Nakhle S. Saba, MD, A. Nicole Lucas, RN, Allison Jacob, MS, Erik Yusko, PhD, Seth M. Steinberg, PhD, Elaine S. Jaffe, Adrian Wiestner, MD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD

Blood (2018) 132 (Supplement 1): 147.

https://doi.org/10.1182/blood-2018-99-112573

Published: 2018

Journal Articles

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

Blood (2017) 130 (Supplement 1): 188.

https://doi.org/10.1182/blood.V130.Suppl_1.188.188

Published: 2017

Journal Articles

End-of-Treatment CT and Serial FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma

Christopher Melani, MD, Ranjana H. Advani, MD, Mark Roschewski, MD, Kelsey M. Walters, BS, Clara C. Chen, MD, Lucia Barrato, MD, Mark A. Ahlman, MD, Milos D. Miljkovic, MD, Seth M. Steinberg, PhD, Margaret Shovlin, RN, Kieron Dunleavy, MD, Stefania Pittaluga, MD PhD, Elaine S. Jaffe, MD, Wyndham H. Wilson, MD PhD

Blood (2017) 130 (Supplement 1): 2859.

https://doi.org/10.1182/blood.V130.Suppl_1.2859.2859

Published: 2017

Journal Articles

Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma

Mark Roschewski, MD, Kieron Dunleavy, MD, Sattva S. Neelapu, MD, Stefania Pittaluga, MD PhD, Christopher Joseph Melani, MD, Elaine S. Jaffe, MD, Margaret Shovlin, RN, Beryl Crossley, BS, Katie Kong, BS, Allison Jacob, MD, Larry Kwak, Wyndham H. Wilson, MD PhD

Blood (2016) 128 (22): 2943.

https://doi.org/10.1182/blood.V128.22.2943.2943

Published: 2016

Journal Articles

DA-EPOCH-R in Primary Mediastinal B-Cell Lymphoma; Analysis of End of Therapy FDG-PET and Outcome

Christopher Joseph Melani, MD, Ranjana Advani, MD, Clara C. Chen, MD, Kelsey M. Walters, BS, David Venzon, PhD, Seth M. Steinberg, PhD, Margaret Shovlin, RN, Elaine S. Jaffe, MD, Stefania Pittaluga, MD PhD, Mark Roschewski, MD, Wyndham H. Wilson, MD PhD, Kieron Dunleavy, MD

Blood (2016) 128 (22): 1116.

https://doi.org/10.1182/blood.V128.22.1116.1116

Published: 2016

Journal Articles

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R

Blood (2015) 126 (23): 342.

https://doi.org/10.1182/blood.V126.23.342.342

Published: 2015

Journal Articles

Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma

Kieron Dunleavy, MD, Catherine E. Lai, MD, Mark Roschewski, MD, Jennifer N Brudno, MD, Brigitte Widemann, MD, Stefania Pittaluga, MD PhD, Elaine S Jaffe, MD, Andrea N Lucas, RN, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Pamela Harris, MD, Diane Cole, John A Butman, MD, Richard F Little, MD, Louis M Staudt, MD, Wyndham H Wilson, MD PhD

Blood (2015) 126 (23): 472.

https://doi.org/10.1182/blood.V126.23.472.472

Published: 2015

Journal Articles

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Kieron Dunleavy, MD, Michelle Fanale, MD, Ann LaCasce, MD, Ariela Noy, Paolo Caimi, MD, Samir Parekh, MD, John W Hayslip, MD, Deepa Jagadeesh, MD MPH, Raymond S Lord, Mary J Lechowicz, MD, Rakesh Gaur, MD, Andrea Lucas, RN, Louis M Staudt, MD PhD, Seth M. Steinberg, PhD, Brad Kahl, MD, Jonathan W. Friedberg, MD, Richard F Little, MPH, MD, Nancy L Bartlett, MD, Wyndham H Wilson, MD PhD

Blood (2014) 124 (21): 395.

https://doi.org/10.1182/blood.V124.21.395.395

Published: 2014

Journal Articles

Ongoing Activation of the BCR, NFκB, and Proliferation Pathways in Mantle Cell Lymphoma: Direct in Vivo Evidence for the Role of the Lymph Node Microenvironnment

Nakhle Saba, MD, Delong Liu, PhD, Sarah E. M. Herman, PhD, Cliona Grant, MD, Kieron Dunleavy, MD, Stefania Pittaluga, Wyndham Wilson, MD PhD, Adrian Wiestner, MD PhD

Blood (2014) 124 (21): 2991.

https://doi.org/10.1182/blood.V124.21.2991.2991

Published: 2014

Journal Articles

Pharmacokinetics and Tolerability of Etoposide in Newly Diagnosed Lymphoma Patients with Hepatic Impairment

Catherine Lai, MD MPH, Diane Cole, Nicole Lucas, RN, Seth M. Steinberg, PhD, Brigitte C Widemann, MD, Kieron Dunleavy, MD, Wyndham H Wilson, MD PhD

Blood (2014) 124 (21): 4445.

https://doi.org/10.1182/blood.V124.21.4445.4445

Published: 2014

Journal Articles

Monitoring of Circulating Tumor DNA As Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

Mark Roschewski, MD, Kieron Dunleavy, MD, Stefania Pittaluga, Katie Kong, Margaret Shovlin, RN, Elaine S. Jaffe, Louis M. Staudt, MD PhD, Catherine Lai, MD MPH, Clara C. Chen, MD, Jianbiao Zheng, PhD, Thomas D. Willis, PhD, Malek Faham, Wyndham H Wilson, MD PhD

Blood (2014) 124 (21): 139.

https://doi.org/10.1182/blood.V124.21.139.139

Published: 2014

Journal Articles

Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy

Kieron Dunleavy, MD, Stefania Pittaluga, MD, Margaret Shovlin, RN, Svetlana Pack, Seth M. Steinberg, PhD, Catherine E. Lai, MD, Cliona Grant, MD, Eric D. Hsi, MD, Louis M. Staudt, MD, PhD, Elaine S. Jaffe, MD, Wyndham H Wilson, MD, PhD

Blood (2013) 122 (21): 3029.

https://doi.org/10.1182/blood.V122.21.3029.3029

Published: 2013

Journal Articles

High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R

Violetta V. Leshchenko, PhD, Pei-Yu Kuo, MS, Deepak Perumal, PhD, Melissa J Fazzari, PhD, Francine E. Garrett-Bakelman, MD, PhD, Nakhle S Saba, MD, Delong Liu, PhD, Weijia Zhang, PhD, Joshua Brody, MD, Ari M. Melnick, MD, Kieron Dunleavy, MD, Wyndham H Wilson, MD, PhD, Adrian Wiestner, MD, PhD, Samir Parekh, MD

Blood (2013) 122 (21): 3760.

https://doi.org/10.1182/blood.V122.21.3760.3760

Published: 2013

Journal Articles

DNA Sequencing-Based Monitoring Of Serum Predicts Clinical Relapse Before CT Imaging in Diffuse Large B-Cell Lymphoma

Mark Roschewski, MD, Stefania Pittaluga, MD, Kieron Dunleavy, MD, Katherine Kong, MS, Margaret Shovlin, RN, Elaine S. Jaffe, MD, Louis M. Staudt, MD, PhD, Jianbiao Zheng, PhD, Tom Willis, PhD, Malek Faham, MD, PhD, Wyndham H Wilson, MD, PhD

Blood (2013) 122 (21): 1767.

https://doi.org/10.1182/blood.V122.21.1767.1767

Published: 2013

NARROW

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell Lymphomas

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR

Short-Course Therapy in Newly Diagnosed Immunodeficiency-Associated Aggressive B-Cell Lymphoma

C-Myc Driven Tolerogenic Tumor Microenvironment (TME) in Mantle Cell Lymphoma (MCL) Is Overcome By Bromodomain Inhibition

Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

End-of-Treatment CT and Serial FDG-PET Imaging to Assess Residual Disease in Primary Mediastinal B-Cell Lymphoma

Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma

DA-EPOCH-R in Primary Mediastinal B-Cell Lymphoma; Analysis of End of Therapy FDG-PET and Outcome

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R

Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma

Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma

Ongoing Activation of the BCR, NFκB, and Proliferation Pathways in Mantle Cell Lymphoma: Direct in Vivo Evidence for the Role of the Lymph Node Microenvironnment

Pharmacokinetics and Tolerability of Etoposide in Newly Diagnosed Lymphoma Patients with Hepatic Impairment

Monitoring of Circulating Tumor DNA As Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy

High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R

DNA Sequencing-Based Monitoring Of Serum Predicts Clinical Relapse Before CT Imaging in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only